KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS respond to treatments differently.  

​

We founded KRAS Kickers to actively monitor and share KRAS-related research developments, information and clinical trials within the community that will benefit the most, us.  We are the patients that need the best outcomes to live our lives.